Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Blum A, Bazou D, O'Gorman P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Smoldering multiple myeloma risk factor biomarker genomic aberrations Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5ba3e1320cb1480eaabafb1d21a824b7
record_format	dspace
spelling	oai:doaj.org-article:5ba3e1320cb1480eaabafb1d21a824b72021-12-02T06:25:36ZSmoldering multiple myeloma: prevalence and current evidence guiding treatment decisions1179-9889https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b72018-04-01T00:00:00Zhttps://www.dovepress.com/smoldering-multiple-myeloma-prevalence-and-current-evidence-guiding-tr-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined significance (MGUS), SMM has a much higher risk of progression to MM. Thanks to advances in our understanding of the risk factors, the subset of patients with ultra-high risk of progression to MM (80%–90% at 2 years) has been identified. The revision of the diagnostic criteria resulted in changes in the management of this cohort of patients. In contrast to the management guidelines for MGUS patients, SMM patients need to be studied more intensively in order to identify biomarkers necessary for accurate risk stratification. In this review, we focus on the risk of progression from SMM to MM, as well as the influence of early treatment on overall survival, time to progression and quality of life. Keywords: smoldering multiple myeloma, risk factor, biomarker, genomic aberrations, glycan analysisBlum ABazou DO'Gorman PDove Medical PressarticleSmoldering multiple myelomarisk factorbiomarkergenomic aberrationsDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 8, Pp 21-31 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Smoldering multiple myeloma risk factor biomarker genomic aberrations Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Smoldering multiple myeloma risk factor biomarker genomic aberrations Diseases of the blood and blood-forming organs RC633-647.5 Blum A Bazou D O'Gorman P Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
description	Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined significance (MGUS), SMM has a much higher risk of progression to MM. Thanks to advances in our understanding of the risk factors, the subset of patients with ultra-high risk of progression to MM (80%–90% at 2 years) has been identified. The revision of the diagnostic criteria resulted in changes in the management of this cohort of patients. In contrast to the management guidelines for MGUS patients, SMM patients need to be studied more intensively in order to identify biomarkers necessary for accurate risk stratification. In this review, we focus on the risk of progression from SMM to MM, as well as the influence of early treatment on overall survival, time to progression and quality of life. Keywords: smoldering multiple myeloma, risk factor, biomarker, genomic aberrations, glycan analysis
format	article
author	Blum A Bazou D O'Gorman P
author_facet	Blum A Bazou D O'Gorman P
author_sort	Blum A
title	Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_short	Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_full	Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_fullStr	Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_full_unstemmed	Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
title_sort	smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b7
work_keys_str_mv	AT bluma smolderingmultiplemyelomaprevalenceandcurrentevidenceguidingtreatmentdecisions AT bazoud smolderingmultiplemyelomaprevalenceandcurrentevidenceguidingtreatmentdecisions AT ogormanp smolderingmultiplemyelomaprevalenceandcurrentevidenceguidingtreatmentdecisions
_version_	1718399933470474240

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

Ejemplares similares